News headlines about ObsEva SA (NASDAQ:OBSV) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ObsEva SA earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.3121864154486 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ObsEva SA (OBSV) traded down 0.25% during midday trading on Thursday, reaching $7.98. The company’s stock had a trading volume of 174,908 shares. ObsEva SA has a 12-month low of $5.00 and a 12-month high of $14.69. The firm has a 50 day moving average price of $7.30 and a 200-day moving average price of $9.29. The company’s market cap is $212.45 million.
ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings data on Thursday, May 18th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.17. On average, equities research analysts predict that ObsEva SA will post ($2.04) earnings per share for the current fiscal year.
OBSV has been the topic of several analyst reports. Credit Suisse Group reissued an “outperform” rating and issued a $27.00 target price on shares of ObsEva SA in a report on Tuesday, April 18th. Zacks Investment Research raised ObsEva SA from a “sell” rating to a “hold” rating in a report on Tuesday, May 30th. Finally, HC Wainwright initiated coverage on ObsEva SA in a report on Thursday, June 29th. They issued a “buy” rating and a $27.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $24.00.
TRADEMARK VIOLATION WARNING: This news story was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/07/27/obseva-sa-nasdaqobsv-getting-somewhat-favorable-news-coverage-study-finds.html.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.
